Cargando…

The Phenotype of Circulating Follicular-Helper T Cells in Patients with Rheumatoid Arthritis Defines CD200 as a Potential Therapeutic Target

Rheumatoid arthritis (RA) is a systemic autoimmune disease primarily affecting synovial joints in which the development of autoantibodies represents a failure of normal tolerance mechanisms, suggesting a role for follicular helper T cells (T(FH)) in the genesis of autoimmunity. To determine whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakera, Aron, Bennett, Sophia C., Morteau, Olivier, Bowness, Paul, Luqmani, Raashid A., Cornall, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471455/
https://www.ncbi.nlm.nih.gov/pubmed/23091555
http://dx.doi.org/10.1155/2012/948218
_version_ 1782246433638842368
author Chakera, Aron
Bennett, Sophia C.
Morteau, Olivier
Bowness, Paul
Luqmani, Raashid A.
Cornall, Richard J.
author_facet Chakera, Aron
Bennett, Sophia C.
Morteau, Olivier
Bowness, Paul
Luqmani, Raashid A.
Cornall, Richard J.
author_sort Chakera, Aron
collection PubMed
description Rheumatoid arthritis (RA) is a systemic autoimmune disease primarily affecting synovial joints in which the development of autoantibodies represents a failure of normal tolerance mechanisms, suggesting a role for follicular helper T cells (T(FH)) in the genesis of autoimmunity. To determine whether quantitative or qualitative abnormalities in the circulating T(FH) cell population exist, we analysed by flow cytometry the number and profile of these cells in 35 patients with RA and 15 matched controls. Results were correlated with patient characteristics, including the presence of autoantibodies, disease activity, and treatment with biologic agents. Circulating T(FH) cells from patients with RA show significantly increased expression of the immunoglobulin superfamily receptor CD200, with highest levels seen in seropositive patients (P = 0.0045) and patients treated with anti-TNFα agents (P = 0.0008). This occurs in the absence of any change in T(FH) numbers or overt bias towards Th1, Th2, or Th17 phenotypes. CD200 levels did not correlate with DAS28 scores (P = 0.887). Although the number of circulating T(FH) cells is not altered in the blood of patients with RA, the T(FH) cells have a distinct phenotype. These differences associate T(FH) cells with the pathogenesis of RA and support the relevance of the CD200/CD200R signalling pathway as a potential therapeutic target.
format Online
Article
Text
id pubmed-3471455
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-34714552012-10-22 The Phenotype of Circulating Follicular-Helper T Cells in Patients with Rheumatoid Arthritis Defines CD200 as a Potential Therapeutic Target Chakera, Aron Bennett, Sophia C. Morteau, Olivier Bowness, Paul Luqmani, Raashid A. Cornall, Richard J. Clin Dev Immunol Clinical Study Rheumatoid arthritis (RA) is a systemic autoimmune disease primarily affecting synovial joints in which the development of autoantibodies represents a failure of normal tolerance mechanisms, suggesting a role for follicular helper T cells (T(FH)) in the genesis of autoimmunity. To determine whether quantitative or qualitative abnormalities in the circulating T(FH) cell population exist, we analysed by flow cytometry the number and profile of these cells in 35 patients with RA and 15 matched controls. Results were correlated with patient characteristics, including the presence of autoantibodies, disease activity, and treatment with biologic agents. Circulating T(FH) cells from patients with RA show significantly increased expression of the immunoglobulin superfamily receptor CD200, with highest levels seen in seropositive patients (P = 0.0045) and patients treated with anti-TNFα agents (P = 0.0008). This occurs in the absence of any change in T(FH) numbers or overt bias towards Th1, Th2, or Th17 phenotypes. CD200 levels did not correlate with DAS28 scores (P = 0.887). Although the number of circulating T(FH) cells is not altered in the blood of patients with RA, the T(FH) cells have a distinct phenotype. These differences associate T(FH) cells with the pathogenesis of RA and support the relevance of the CD200/CD200R signalling pathway as a potential therapeutic target. Hindawi Publishing Corporation 2012 2012-10-04 /pmc/articles/PMC3471455/ /pubmed/23091555 http://dx.doi.org/10.1155/2012/948218 Text en Copyright © 2012 Aron Chakera et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Chakera, Aron
Bennett, Sophia C.
Morteau, Olivier
Bowness, Paul
Luqmani, Raashid A.
Cornall, Richard J.
The Phenotype of Circulating Follicular-Helper T Cells in Patients with Rheumatoid Arthritis Defines CD200 as a Potential Therapeutic Target
title The Phenotype of Circulating Follicular-Helper T Cells in Patients with Rheumatoid Arthritis Defines CD200 as a Potential Therapeutic Target
title_full The Phenotype of Circulating Follicular-Helper T Cells in Patients with Rheumatoid Arthritis Defines CD200 as a Potential Therapeutic Target
title_fullStr The Phenotype of Circulating Follicular-Helper T Cells in Patients with Rheumatoid Arthritis Defines CD200 as a Potential Therapeutic Target
title_full_unstemmed The Phenotype of Circulating Follicular-Helper T Cells in Patients with Rheumatoid Arthritis Defines CD200 as a Potential Therapeutic Target
title_short The Phenotype of Circulating Follicular-Helper T Cells in Patients with Rheumatoid Arthritis Defines CD200 as a Potential Therapeutic Target
title_sort phenotype of circulating follicular-helper t cells in patients with rheumatoid arthritis defines cd200 as a potential therapeutic target
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471455/
https://www.ncbi.nlm.nih.gov/pubmed/23091555
http://dx.doi.org/10.1155/2012/948218
work_keys_str_mv AT chakeraaron thephenotypeofcirculatingfollicularhelpertcellsinpatientswithrheumatoidarthritisdefinescd200asapotentialtherapeutictarget
AT bennettsophiac thephenotypeofcirculatingfollicularhelpertcellsinpatientswithrheumatoidarthritisdefinescd200asapotentialtherapeutictarget
AT morteauolivier thephenotypeofcirculatingfollicularhelpertcellsinpatientswithrheumatoidarthritisdefinescd200asapotentialtherapeutictarget
AT bownesspaul thephenotypeofcirculatingfollicularhelpertcellsinpatientswithrheumatoidarthritisdefinescd200asapotentialtherapeutictarget
AT luqmaniraashida thephenotypeofcirculatingfollicularhelpertcellsinpatientswithrheumatoidarthritisdefinescd200asapotentialtherapeutictarget
AT cornallrichardj thephenotypeofcirculatingfollicularhelpertcellsinpatientswithrheumatoidarthritisdefinescd200asapotentialtherapeutictarget
AT chakeraaron phenotypeofcirculatingfollicularhelpertcellsinpatientswithrheumatoidarthritisdefinescd200asapotentialtherapeutictarget
AT bennettsophiac phenotypeofcirculatingfollicularhelpertcellsinpatientswithrheumatoidarthritisdefinescd200asapotentialtherapeutictarget
AT morteauolivier phenotypeofcirculatingfollicularhelpertcellsinpatientswithrheumatoidarthritisdefinescd200asapotentialtherapeutictarget
AT bownesspaul phenotypeofcirculatingfollicularhelpertcellsinpatientswithrheumatoidarthritisdefinescd200asapotentialtherapeutictarget
AT luqmaniraashida phenotypeofcirculatingfollicularhelpertcellsinpatientswithrheumatoidarthritisdefinescd200asapotentialtherapeutictarget
AT cornallrichardj phenotypeofcirculatingfollicularhelpertcellsinpatientswithrheumatoidarthritisdefinescd200asapotentialtherapeutictarget